Ultrasensitive direct impedimetric immunosensor for detection of serum HER2.

作者: Shikha Sharma , Julia Zapatero-Rodríguez , Rahul Saxena , Richard O’Kennedy , Sudha Srivastava

DOI: 10.1016/J.BIOS.2018.01.056

关键词:

摘要: Abstract Assesment of human epidermal growth factor receptor 2 status is a key prompting definitive treatment decisions that help in reducing mortality rates associated with breast cancer. In this article, highly sensitive and low-cost impedimetric immunosensor using single-chain fragment variable antibody fragments was developed for quantitative detection from serum employing gold nanoparticle-modified disposable screen-printed carbon electrodes. The nanoparticles facilitate fast electron transfer offer biocompatible surface immobilization small an oriented manner, resulting improved antigen binding efficiency. fragment-modified screen printed exhibits wide dynamic range 0.01–100 ng mL−1 limit 0.01 ng mL−1. advantages offered by platform terms high sensitivity, broad demonstrates great potential monitoring levels the management other cancers.

参考文章(23)
D. Lüftner, D. W. Chan, G. B. Cook, D. R. Cambetas, K. K. Yeung, J. L. Goldblatt, W. J. Allard, M. K. Schwartz, I. E. Neaman, M. Hussain, Clinical utility of serum HER-2/neu testing on the bayer immuno 1® automated system in breast cancer Anticancer Research. ,vol. 21, pp. 1465- 1470 ,(2001)
Ragini Raghav, Sudha Srivastava, Core–shell gold–silver nanoparticles based impedimetric immunosensor for cancer antigen CA125 Sensors and Actuators B-chemical. ,vol. 220, pp. 557- 564 ,(2015) , 10.1016/J.SNB.2015.05.108
Andrea Ravalli, Carolina Gomes da Rocha, Hideko Yamanaka, Giovanna Marrazza, A label-free electrochemical affisensor for cancer marker detection: The case of HER2 Bioelectrochemistry. ,vol. 106, pp. 268- 275 ,(2015) , 10.1016/J.BIOELECHEM.2015.07.010
Carlos F. Barbas, Phage Display: A Laboratory Manual ,(2004)
Terry Pry, David A Armbruster, Limit of blank, limit of detection and limit of quantitation. The Clinical biochemist. Reviews / Australian Association of Clinical Biochemists. ,vol. 29, ,(2008)
C. Papila, H. Uzun, H. Balci, H. Zerdali, C. Sezgin, Günay Can, H. Yanardag, Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors Medical Oncology. ,vol. 26, pp. 151- 156 ,(2009) , 10.1007/S12032-008-9098-3
Edith A. Perez, Javier Cortés, Ana Maria Gonzalez-Angulo, John M.S. Bartlett, HER2 testing: Current status and future directions Cancer Treatment Reviews. ,vol. 40, pp. 276- 284 ,(2014) , 10.1016/J.CTRV.2013.09.001
John T. Gohring, Paul S. Dale, Xudong Fan, Detection of HER2 breast cancer biomarker using the opto-fluidic ring resonator biosensor Sensors and Actuators B-chemical. ,vol. 146, pp. 226- 230 ,(2010) , 10.1016/J.SNB.2010.01.067
Dana Olsen, Jan Trøst Jørgensen, Companion Diagnostics for Targeted Cancer Drugs - Clinical and Regulatory Aspects Frontiers in Oncology. ,vol. 4, pp. 105- 105 ,(2014) , 10.3389/FONC.2014.00105